Home >> About

News & Events

Philadelphia, PA January 14, 2015 - Lonnie and Sharon Moulder, alumni of the Temple University School of Pharmacy, have pledged $5 million to endow the Moulder Center for Drug Discovery Research.  The Moulders donated $500,000 to help establish the academic drug discover center in 2007.

Philadelphia, PA December 14, 2014 - Laura H. Carnell Professor of Medicinal Chemistry, Associate Dean for Research and Director of the Moulder Center for Drug Discovery Research in Temple’s School of Pharmacy Magid Abou-Gharbia has won the prestigious Grand Hamdan International Award in Drug Discovery. Dr. Abou-Gharbia won the award in recognition for his outstanding contributions and pioneering work in medicinal chemistry and the discovery of several drugs, including the anti-cancer drug Torisel®, as well as the antidepressants Effexor® and Pristiq®.

December 11, 2014 - The Moulder Center for Drug Discovery Research will participate in the newly awarded NIH R01 grant entitled "“D3 Receptor Compounds for the Treatment of Psychostimulant Abuse” (2R01DA023957-06A1).  This 5 year program will be pursued in collaboration with Dr. Robert Luedtke (University of North Texas Health Science Center), Dr. Robert Mach (University of Pennsylvania), and Dr. Janet Neiesewander (Arizona State University).  Dr. Benjamin E Blass will serve as the principle investigator at the Moulder Center.

Each year the Philadelphia Business Journal announces Innovation Awards in several categories of endeavor. At an Award Reception on Thursday, October 24, 2014, Dr. Magid Abou-Gharbia received the Educator/Researcher Innovation Award of the Year 2014, and was recognized as the first among several candidates.

Philadelphia, PA Spetember 14, 2014 - The Moulder Center for Drug Discovery Research will participate in the newly awarded NIH R01 grant entitled "Targeting DNA Repair to Eradicate Tyrosine Kinase Inhibitor-Refractory/Resistant Chronic Myelogenous Lekemia" (5R01CA186238-02).  This five year, $2.5 MM program will be pursued as a collaborative effort with Dr. Tomasz Skorski (Temple School of Medicine) and Dr. Wayne E Childers (Temple School of Pharmacy, Moulder Center).

Magid Abou-Gharbia, Laura H. Carnell Professor of Medicinal Chemistry, was one of five former Wyeth (now Pfizer) scientists to be honored with the American Chemical Society’s 2014 Heroes of Chemistry award. He and his colleagues were recognized for their discovery of the antidepressant Effexor, regarded as a breakthrough therapy for depression, which has benefited over 25 million patients worldwide. Abou-Gharbia, who is also associate dean for research and director of the Moulder Center for Drug Discovery Research in the School of Pharmacy, was formerly senior vice president and head of chemical and screening sciences at Wyeth.

Philadelphia, PA August 13, 2014 - The Moulder Center for Drug Discovery Research will participate in the newly awarded NIH R01 grant entitled "Spectral Revelations of Mitochondrial Ca2+ Interactome" (1R01GM109882-01).  This four year program will be pursued as a collaborative effort with Dr. Jeffrey Caplan (University of Delaware), Dr. Filippo Mancia (Columbia University Medical Center) Dr. Madesh Muniswamy (Temple University School of Medicine), and Dr. Salim Merali (Temple School of Pharmacy, Moulder Center).

The Moulder Center for Drug Discovery Research has been awarded a 5 year NIH R01 grant to support the identification of novel therapies for the treatment of cocaine addiction and withdrawal.  Cocaine addiction is a chronic disease characterized by an inability to regulate drug-seeking behavior. The lifetime prevalence of cocaine addiction in the United States is 15.4% and there currently are no FDA-approved treatments for cocaine addiction.  The program will focus on developing compounds capable of increasing the expression of Glutamate Transporter 1 (GLT-1), an important component of glutamate re-uptake in the central nervous system.  Colleagues at John Hopkins University and the University of Florida will be collaborating with Moulder Center scientists on this $1.98 million project over the next 5 years.

The Moulder Center also added a powerful new research tool thanks to the efforts of Dr. Marlene Jacobson, who led a successful effort to obtain a National Institutes of Health Shared Instrument grant in June 2104 (NIH Project #1S10OD018195-01).  This $267K grant supported the acquisition of a Hamamatsu Functional Drug Discovery Screening System (FDSS) μCell instrument, a kinetic plate reader with an integrated dispensing head and imaging-based detector.  The FDSS μCell instrument provides the Moulder Center for Drug Discovery Research and the Temple University research community a high throughput screening platform to measure activities on G-protein coupled receptors and ion channels.  The addition of this system compliments the Moulder Centers existing infrastructure and represents a continuation of the Moulder Center’s commitment to explore cutting edge research and technology.

Martinsried/Munich, Germany, and Philadelphia, USA, April 29, 2014: MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and The Moulder Center for Drug Discovery Research, a unit of Temple University’s School of Pharmacy, Philadelphia, Pa., USA, today announced a strategic alliance focused on the discovery of new therapeutic antibodies. Under the terms of the agreement, the Moulder Center will receive access to MorphoSys’s Ylanthia® technology for use in validating new disease-related targets and generating therapeutic antibody candidates. MorphoSys will receive an exclusive option to develop any resulting antibodies. Financial details of the agreement were not disclosed.

Pages

Temple University
Moulder Center for Drug Discovery Research

Temple University School of Pharmacy
3307 N Broad Street
Philadelphia, PA 19140